Fergus Gleeson

Novel Clinical Imaging Research Group

Our group focuses on using imaging techniques in small-scale trials with the particular ambitions of improving the mechanisms of data analysis and correlating the imaging data provided with histology and treatment outcomes.

+44 (0)1865 235746

Research Summary

There are now an unprecedented number of imaging techniques being developed that are potentially available for clinical practice, for instance, dynamic contrast enhanced MRI, perfusion CT, novel PET tracers, and hyperpolarized xenon. These techniques have yet to be shown to impact on clinical practice and often require modification of either scanning technique or
methods for data analysis. There is also a significant amount of data available from current imaging techniques already in use that may potentially be used as a prognostic biomarker, predict treatment response, a nd modify treatment.
We have focused on a small number of different areas: angiogenesis imaging using dynamic contrast enhanced MRI and perfusion CT, dynamic FDG PET imaging, and the novel 18 F PET integrin imaging agent fluciclatide.
18 F fluciclatide PET-CT images of a patient with bilateral scapula bone metastases from renal cancer. Image A is pre-antiangiogenic therapy demonstrating active angiogenesis at the edge of the metastases. Image B confirms the anti-angiogenic effect of treatment with decreased integrin activity at the sites of pre-treatment avidity.



We have also developed novel data analysis techniques for use in hyperpolarized xenon MRI. Trials in normal healthy volunteers, patients with COPD and lung cancer are currently underway, and have enabled us to develop methods of lobar analysis of ventilation and emphysema correlated with CT and pulmonary function. The aim is to develop an imaging tool that would, for instance, predict the change in lung function following lobar resection or following radiotherapy.


3-D hyperpolarized xenon ventilation MRI image


Fergus Gleeson is a Consultant Radiologist and Professor of Radiology in Oxford. He trained in Cambridge, Papworth and London, and was a Fellow in Radiology at UCLA in Los Angeles. He was appointed to Oxford in 1992, and is head of academic radiology, the director of the Oxford Imaging Trials Unit, and a Divisional Director for the Oxford University Hospitals NHS Trust. His specialist interests are in PET and hyperpolarized xenon MRI.



The impact of heterogeneity and uncertainty on prediction of response to therapy using dynamic MRI data. Bhushan M, Schnabel JA, Chappell M, Gleeson F, Anderson M, Franklin J, Brady SM, Jenkinson M. Med Image Comput Comput Assist Interv. 2013;16(Pt 1):316-23

Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.Kraeber-Bodéré F, Carlier T, Naegelen VM, Shochat E, Lumbroso J, Trampal C, Nagarajah J, Chua S, Hugonnet F, Stokkel M, Gleeson F, Tessier J. J Nucl Med. 2012 Dec;53(12):1836-46.

Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer. Gillies RS, Middleton MR, Blesing C, Patel K, Warner N, Marshall RE, Maynard ND, Bradley KM, Gleeson FV. Eur Radiol. 2012 Sep;22(9):2035-43.

Associated Researchers



About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.